Skip to content

This website is a third-party information service. It does not provide medical care or operate a treatment facility.

Phase 1 Cancer Trials

Kentucky

Phase 1 cancer trials in Kentucky

44 Phase 1 cancer studies are recruiting participants at sites in 3 cities across Kentucky as of November 17, 2026, according to ClinicalTrials.gov.

Call (888) 927-9038
  • No cost to ask
  • Taking part is voluntary
  • Studies are independently reviewed

Every Kentucky city with a recruiting study

By research area: Lung Cancer (20), Lymphoma (8), Breast Cancer (5), Melanoma (5), Pancreatic Cancer (5), Prostate Cancer (1).

Louisville (26), Lexington (18), Edgewood (2).

The number after each city is how many studies have a recruiting site there. A study with sites in several cities is counted in each one.

Breast cancer: recently updated in Kentucky

Basic details from each study's public record (the 12 most recently updated of 44). Select a study to read the full record on ClinicalTrials.gov, including how to contact its team.

  1. A Phase 1 Study of LNCB74 in Advanced Solid Tumors

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    LigaChem Biosciences, Inc.
    Recruiting in
    Edgewood
    Registry record
    NCT06774963 · updated

Source: ClinicalTrials.gov. Data processed . See every breast cancer study recruiting in Kentucky on ClinicalTrials.gov.

Lung cancer: recently updated in Kentucky

  1. Testing the Combination of an Anti-cancer Drug, Iadademstat, With Other Anti-cancer Drugs (Atezolizumab or Durvalumab) at Improving Outcomes for Small Cell Lung Cancer

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Recruiting in
    Lexington
    Registry record
    NCT06287775 · updated
  2. DAREON®-36: A Study to Test Obrixtamig in Combination With ZL-1310 in People With Advanced Small Cell Lung Cancer or Other Neuroendocrine Cancers

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Boehringer Ingelheim
    Recruiting in
    Lexington
    Registry record
    NCT07707895 · updated
  3. A Clinical Study of Gocatamig (MK-6070) and Infinatamab Deruxtecan (MK-2400) in People With Small Cell Lung Cancer (MK-6070-003)

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Recruiting in
    Edgewood
    Registry record
    NCT07227597 · updated
  4. Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Inhibrx Biosciences, Inc
    Recruiting in
    Louisville
    Registry record
    NCT04198766 · updated
  5. Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Revolution Medicines, Inc.
    Recruiting in
    Lexington
    Registry record
    NCT07397338 · updated
  6. Safety and Efficacy of OBX-115 in Advanced Solid Tumors

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Obsidian Therapeutics, Inc.
    Recruiting in
    Louisville
    Registry record
    NCT06060613 · updated

Source: ClinicalTrials.gov. Data processed . See every lung cancer study recruiting in Kentucky on ClinicalTrials.gov.

Melanoma: recently updated in Kentucky

  1. A Study of BI 3810944 in Patients With Advanced Cancer

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Boehringer Ingelheim
    Recruiting in
    Louisville
    Registry record
    NCT07224425 · updated

Source: ClinicalTrials.gov. Data processed . See every melanoma study recruiting in Kentucky on ClinicalTrials.gov.

Pancreatic cancer: recently updated in Kentucky

  1. Testing the Safety and Tolerability of the Anti-cancer Drugs Trastuzumab Deruxtecan and Neratinib for Cancers With Changes in the HER2 Gene

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Recruiting in
    Lexington
    Registry record
    NCT05372614 · updated
  2. Study of RYZ401 in Subjects With Solid Tumors Expressing SSTRs.

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    RayzeBio, Inc.
    Recruiting in
    Lexington
    Registry record
    NCT07165132 · updated
  3. Lead-212 PSV359 Therapy for Patients With Solid Tumors

    • Phase 1/2
    • Ages 18 to 90
    • All sexes
    Sponsor
    Perspective Therapeutics
    Recruiting in
    Lexington
    Registry record
    NCT06710756 · updated

Source: ClinicalTrials.gov. Data processed . See every pancreatic cancer study recruiting in Kentucky on ClinicalTrials.gov.

Ask about studies in Kentucky

Tell us what you are looking for and a coordinator will contact you to talk through your options. Asking does not commit you to anything.

How should we reach you?
Add a message or the best time to reach you (optional)

Please do not include detailed medical information.

Before you contact a study

About these listings

These listings come from ClinicalTrials.gov, the study registry run by the U.S. National Library of Medicine. The data were processed on November 17, 2026. We show part of each public record (its title, phase, sponsor, basic eligibility and sites in this area) exactly as registered, and we group studies by place. Nothing in a record is reworded. This site lists only studies that are in Phase 1, including early Phase 1 and combined Phase 1/2, as each study is coded in the registry.

Phase 1 Cancer Trials does not run these studies and is not affiliated with their sponsors. A listing is not a recommendation, and only a study's own team can tell you whether you may be eligible. Follow the link on any study to read its full record and contact that team directly, or ask us and a coordinator will help you understand your options. How we source and check what we publish.

Sources and further reading

Ask about a study

A coordinator will contact you. Asking does not commit you to anything.

Call (888) 927-9038

or send a short form

How should we reach you?

Call